A cocktail of antibodies against Covid-19 that the British-Swedish laboratory AstraZeneca has been developing for months led to a “67% reduction” in severe or fatal cases in phase 3 clinical trials.
Trials of the AZD7442 drug, consisting of a combination of antibodies, “resulted in a statistically satisfactory reduction” in “severe cases of Covid-19 or deaths from the disease compared to a placebo in non-hospitalized patients with mild symptoms or moderate, “AstraZeneca explained in a statement.
Participants received the treatment within five days of the first symptoms, and preliminary analysis of the results shows that “AZD7442 reduced the risk of developing severe or fatal coronavirus in 67% of cases in compared to placebo, “the pharmaceutical company noted.
90% of the participants belonged to categories of patients considered high risk, including those with comorbidities.
“As severe COVID-19 cases continue around the world, there is a significant need for new therapies such as AZD7442 to protect vulnerable populations,” he said. Hugh Montgomery, a professor of intensive care medicine at University College London and one of the lead investigators in this clinical trial, which involved 903 people.
AstraZeneca will submit the data to health authorities and has already submitted an application to the US Food and Drug Administration, the FDA, for approval of the drug.
The group announced in March an agreement with the United States to supply up to 700,000 doses of this antibody treatment to the country this year, for a total of US $ 726,000,000.